Osemitamab is under clinical development by Transcenta and currently in Phase II for Lung Cancer. According to GlobalData, Phase II drugs for Lung Cancer have a 36% phase transition success rate (PTSR ...

Target Synonym: CLDN18, Claudin 18, UNQ778/PRO1572, Pulmonary Associated Protein J, Surfactant Associated 5, and Surfactant Associated JClaudin-18, SFTPJ, Claudin 18. ...

Claudin18.2, a known subtype of Claudin18 ... gastric cancer, ovarian cancer, lung cancer, cholangiocarcinoma, among others. As a result, it has become a popular target for immunotherapy, such ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against ...

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic ...

About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of ...

This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against ...

About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of ...